Buprenorphine Cuts Risk for Death After Nonfatal, Opioid-Involved Overdose
THURSDAY, April 13, 2023 (HealthDay News) — Buprenorphine treatment after nonfatal opioid-involved overdose is associated with significant decline in the risk for opioid-involved overdose death, according to a study published online March 10 in the A…
Learn MoreSmartphone-Aided Postoperative Monitoring Effective
THURSDAY, April 13, 2023 (HealthDay News) — Postoperative follow-up using smartphone app-assisted monitoring for patients undergoing breast reconstruction and gynecologic oncology surgery is associated with improved quality of recovery, according to …
Learn MoreSpanish-Only Speakers Have Worse Neurologic Stroke Outcomes
THURSDAY, April 13, 2023 (HealthDay News) — Spanish-only speaking Mexican Americans with ischemic stroke and intracerebral hemorrhage have worse neurologic outcomes than English speakers, according to a study published online April 12 in Neurology.Al…
Learn MoreDonor Sex Does Not Affect Survival in Red-Cell Transfusion
THURSDAY, April 13, 2023 (HealthDay News) — Donor sex has no impact on recipient mortality in red-cell transfusion, according to a study published in the April 13 issue of the New England Journal of Medicine.Michaël Chassé, M.D., Ph.D., from the Cent…
Learn MoreDersimelagon Beneficial for Erythropoietic, X-Linked Protoporphyria
THURSDAY, April 13, 2023 (HealthDay News) — For patients with erythropoietic protoporphyria or X-linked protoporphyria, dersimelagon at doses of 100 and 300 mg significantly increases the duration of symptom-free sunlight exposure, according to a stu…
Learn MoreProphylactic Use of Tranexamic Acid Not Beneficial in Cesarean Delivery
THURSDAY, April 13, 2023 (HealthDay News) — For patients undergoing cesarean delivery, prophylactic use of tranexamic acid does not lead to a lower risk for a composite of maternal death or blood transfusion, according to a study published in the Apr…
Learn MoreAddition of Metastasis-Directed Therapy Increases PFS in Prostate Cancer
THURSDAY, April 13, 2023 (HealthDay News) — The addition of metastasis-directed therapy (MDT), consisting of definitive radiation therapy to all sites of disease, to hormone therapy results in improved progression-free survival for men with oligometa…
Learn More